Standardization of T-cell assays in Type I diabetes
Dear Sir, At the third Immunology of Diabetes Society Conference, held recently in Chicago, a number of issues surrounding the question of standardizing T-cell assays were raised. Type I (insulin-dependent) diabetes mellitus is considered to result from a T-cell mediated destruction of the pancreatic beta cells [1] . Multiple studies indicate a variety of aberrations in cellular immune responses in relation to islet autoimmunity [2] . Several discrepancies have, however, also been reported [2] . Many explanations can be given including techniques or culture conditions which are not comparable, differences in populations of patients or control subjects tested and differences in autoantigen preparations. As the first T-cell workshop on this subject (supported by the Juvenile Diabetes Foundation International), which finished recently and was discussed in Chicago indicated, this is a difficult area, but some idea of where efforts could be focused arose. The aim of the first workshop was to Letters 636 appreciate and identify the problems associated with autoreactive T-cell assays in Type I diabetes. In the workshop, a series of candidate autoantigens was analysed for quality by five selected laboratories. Subsequently, these preparations, as well as some control stimuli, were distributed blindly to 26 laboratories world-wide including all expert centres, for analysis in T-cell proliferation assays on 10 recent onset Type I diabetic patients and 10 non-diabetic control subjects. The participants used their own assays and references.
The results of the islet antigen quality control prior to the distribution indicated firstly that the quality of the preparations of recombinant autoantigen requires improvement. For instance, several T-cell clones specific to glutamic acid decarboxylase-65 (GAD 65) were unable to cross react with GAD 65 expressed in baculovirus, yeast or bacteria. Moreover, autoantigens expressed in E. coli interfered with antigen specific proliferation of both T-cell clones and peripheral blood mononuclear cells. Nonetheless, specific responses could be measured for all autoantigen preparations evaluated in the workshop. Secondly, all centres were able to measure T-cell responses to two identical, blinded samples of tetanus toxoid reproducibly, even though the sensitivity and extent of the proliferative response differed considerably. Thirdly, few laboratories could distinguish Type I diabetic patients from non-diabetic control subjects with regard to proliferative responses to individual islet autoantigens, but generally no differences between the two groups could be identified.
In Chicago there was strong and broad support for continuing this programme. Even though the results of the first T-cell workshop may have raised some concern and frustration, we were reminded of how disappointing the early attempts at islet cell autoantibody (ICA) standardization were and how the years of effort eventually paid off.
The problems are now identified and appreciated. Firstly, T-cell responses to autoantigens appear more difficult to measure than those against non-self proteins, perhaps due to relatively low precursor frequencies or regulatory immune responses directed to control autoreactivity. Some assays currently used may not be suitable for detection of T-cell autoimmunity. Secondly, the quality of recombinant autoantigen preparations is critical, and, thus far, largely insufficient. Thirdly, the definition of the non-diabetic control populations used as references is very heterogeneous. As indicated earlier [3] , matching for genetic predisposition (in first instance HLA) is essential in the light of the role of HLA molecules in thymic selection, shaping of the T-cell repertoire and restriction of T-epitope specific T-cell responses. Forthly, the definition of`positivity' requires standardization.
Nonetheless, there is certainly good reason to believe that these problems can be overcome. Several solutions for improving the quality of T-cell assays were proposed. They included the use of a cocktail of control antigens as a standard positive reference (Drs. M. Atkinson and E. Thorsby), addition of low dose IL-2 to prevent apoptosis (Dr. H. M. Dosch), an increase in the number of wells per stimulus beyond triplicates (Dr. L. Harrison), definition of control subjects (Dr. M. Honeyman), evaluation of dose response ranges and definition of a consensus assay. Moreover, development of new techniques, such as ELISPOT assays for cytokine production, limiting dilution analyses and HLA tetramers, must be considered.
A proposal for the next phases of the T-cell standardization workshop has just been finalized. Because of the complexity of the area, it was decided that we should only attempt small steps initially, perhaps with fewer participating laboratories. There will be, however, ample opportunity for all interested laboratories to contribute at some point in the future. The overall aim is to ensure that by the next meeting of the Immunology of Diabetes Society we can report definite and tangible progress in this area. The second workshop on autoreactive T-cells in Type I diabetes will be divided into three phases.
In the first phase, emphasis will be on reproducibility and sensitivity. To assess how the T-cell proliferation measured in one centre compares with another, aliquots of fresh blood will be sent to a limited number of laboratories along with antigens known to give responses, reagents (medium, serum) and a protocol. The same procedure will be repeated with the same blood donor 3 months later. After assay, raw counts per minute would then be reported back to the coordinating laboratory and analysed for evaluation at the next IDS Conference in Bled, Slovenia, in November 1999.
Several laboratories have published data to suggest that they have assays or antigens that can discriminate between Type I diabetic patients and control subjects. Since we do not have a ªgold standardº antigen, we need to evaluate antigens which could be discriminative in a blinded fashion, with the aim of identifying the best practice. This will be the aim of the second phase. For this purpose, a limited number of coded, Type I diabetes-related autoantigens will be made available for distribution.
It is conceivable that, as a result of distinctive features of autoimmunity compared with immunity (e. g. low precursor frequency), T-cell proliferation assays as they are currently carried out are not ideal for studying pathogenesis/prediction/surrogate markers. There is an urgent need for the development and evaluation of novel approaches to measuring T-cell reactivity in Type I diabetes. Assays such as those assessing peptide responses, using ELISPOTS, cytokine measurements, HLA tetramers, limiting dilution analyses etc., or novel modifications of conventional assays (antigen delivery, use of dendritic cells or low dose IL-2) should be assessed. In the third phase, purified autoantigens, similar to those outlined in phase II above, will be made available for groups to aid assay development.
Institutes interested in participating in the second T-cell workshop on autoreactive T-cells in Type I diabetes should contact the representative in the Council of the Immunology of Diabetes Society indicated below.
Yours sincerely, B. O. Roep, on behalf of the Immunology of Diabetes Society T-cell Committee
